106 results
DEFA14A
AEON
AEON Biopharma Inc. - Ordinary Shares
14 May 24
Additional proxy soliciting materials
9:14am
in this Annual Report.
The following summarizes the nature and effect of the identified error:
The Company recorded the write-off of the acquired in-process … of one treatment cycle. Due to the nature of the disease, dosing was tailored to the individual patient based on the patient’s head and neck position
8-K
7sctnb1z
3 May 24
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
4:27pm
8-K
EX-4.1
uk6rkb 6qsvq
17 Apr 24
Entry into a Material Definitive Agreement
4:06pm
8-K
EX-4.1
y3j s5967f1a5pgna
28 Mar 24
Entry into a Material Definitive Agreement
4:06pm
8-K
EX-10.1
g43xzy2qiv38 pj
19 Mar 24
Entry into a Material Definitive Agreement
4:33pm
8-K
EX-10.6
aliusoj1
19 Mar 24
Entry into a Material Definitive Agreement
4:33pm
8-K
EX-10.5
wuxmt9n0dv4j1mb
19 Mar 24
Entry into a Material Definitive Agreement
4:33pm
8-K
EX-4.1
l27snvii
19 Mar 24
Entry into a Material Definitive Agreement
4:33pm
8-K
EX-10.2
n5me1
19 Mar 24
Entry into a Material Definitive Agreement
4:33pm
8-K
EX-10.3
lhbr554ubxcwk
19 Mar 24
Entry into a Material Definitive Agreement
4:33pm